← back to search

Jing Li

Guangzhou University of Chinese Medicine · CN
Area of research
Immunology · Oncology
Research interest
Research interests include Immune Cell Function and Interaction, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, and Immunotherapy and Immune Responses.
h-index
48
citations
9,532
works
268
NIH funding
primary concept
Medicine
email

Recent publications

An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy
Nature Cancer 2025cited by 16position: middledoi
Posttranslational remodeling micelle reverses cell-surface and exosomal PD-L1 immunosuppression in tumors resistant to PD-L1 antibody therapy
Journal of Controlled Release 2025cited by 8position: middledoi
Regulatory KIR <sup>+</sup> CD8 <sup>+</sup> T cells are elevated during human pregnancy
Science Translational Medicine 2025cited by 6position: firstdoi
System Analysis Identifies MYBL2 As a Novel Oncogene Target for Metastatic Prostate Cancer
Journal of Cancer 2025cited by 2position: middledoi
A human autoimmune organoid model reveals IL-7 function in coeliac disease
Nature 2024cited by 58position: middledoi
Targeting myeloid-derived suppressor cells promotes antiparasitic T-cell immunity and enhances the efficacy of PD-1 blockade
Nature Communications 2024cited by 18position: middledoi
Synergistic upregulation of PD‑L1 in tumor cells and CD39 in tumor‑infiltrating CD8<sup>+</sup> T cells leads to poor prognosis in patients with hepatocellular carcinoma
Oncology Letters 2024cited by 6position: middledoi
Author Correction: Targeting myeloid-derived suppressor cells promotes antiparasitic T-cell immunity and enhances the efficacy of PD-1 blockade
Nature Communications 2024cited by 2position: middledoi
A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2
Nature Materials 2023cited by 92position: middledoi
EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors
Science Advances 2023cited by 82position: middledoi
Interleukin-23 receptor signaling impairs the stability and function of colonic regulatory T cells
Cell Reports 2023cited by 45position: middledoi
KIR <sup>+</sup> CD8 <sup>+</sup> T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19
Science 2022cited by 239position: firstdoi
UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced <i>PDL1</i> transcription in triple negative breast cancer
Theranostics 2022cited by 88position: middledoi
Inhibition of UBA6 by inosine augments tumour immunogenicity and responses
Nature Communications 2022cited by 69position: middledoi
Mannose-Derived Carbon Dots Amplify Microwave Ablation-Induced Antitumor Immune Responses by Capturing and Transferring “Danger Signals” to Dendritic Cells
ACS Nano 2021cited by 97position: middledoi
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Frontiers in Genetics 2021cited by 69position: middledoi
MRTF-A-NF-κB/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-β
Experimental & Molecular Medicine 2021cited by 67position: lastdoi
Research Trends and Regulation of CCL5 in Prostate Cancer
OncoTargets and Therapy 2021cited by 30position: middledoi
Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19
Cell 2020cited by 637position: middledoi
Expressions of CD23, IL-17 and MMP-9 in Patients with Colorectal Cancer
Iranian Journal of Public Health 2020cited by 5position: middledoi
Research Advances of Traditional Chinese Medicine in Cancer Immunotherapy
Chinese Medicine and Culture 2020cited by 5position: firstdoi
Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction
Nature 2019cited by 520position: middledoi
NF-κB-driven miR-34a impairs Treg/Th17 balance via targeting Foxp3
Journal of Autoimmunity 2019cited by 97position: middledoi
Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors
Proceedings of the National Academy of Sciences 2018cited by 176position: middledoi
Crosstalk between Epigenetic Modulations in Valproic Acid Deactivated Hepatic Stellate Cells: An Integrated Protein and miRNA Profiling Study
International Journal of Biological Sciences 2018cited by 12position: middledoi
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function
Cell Research 2017cited by 323position: middledoi
Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China
BMC Cancer 2012cited by 79position: middledoi
Experimental study on expression of tissue factor in pterygium
2012cited by 0position: first

Grants

No grants ingested yet.

Frequent collaborators

Liang Li · Justus-Liebig-Universität Gießen2 papers (2024–2024)Hao Wen · Xinjiang Medical University2 papers (2024–2024)Wenbao Zhang · Xinjiang University2 papers (2024–2024)Haoyu Sun · Fudan University2 papers (2024–2024)Yingmei Shao · Xinjiang Medical University2 papers (2024–2024)Yinshi Li · Xinjiang Medical University2 papers (2024–2024)Qian Yu · Wenzhou Medical University2 papers (2024–2024)Bingqing Deng · Sun Yat-sen University2 papers (2024–2024)Xuejiao Kang · Xinjiang Medical University2 papers (2024–2024)H. Wang · Xinjiang Medical University2 papers (2024–2024)Maolin Wang · King University2 papers (2024–2024)Vamsee Mallajosyula · Stanford University2 papers (2023–2025) · 2 papers (2024–2024)Abidan Ainiwaer · Xinjiang Medical University2 papers (2024–2024)Mark M. Davis · Case Western Reserve University2 papers (2023–2025)Renlun Huang · Guangzhou University of Chinese Medicine2 papers (2021–2025)Zibigu Rousu · Xinjiang Medical University2 papers (2024–2024)Tuerganaili Aji · Xinjiang Medical University2 papers (2024–2024)Xuran Zheng · Ministry of Education of the People's Republic of China2 papers (2024–2024)Chuanshan Zhang · Xinjiang University2 papers (2024–2024)